Carbonic Anhydrase IX (CAIX) is a hypoxia and HIF-1 inducible protein that regulates intra-and extracellular pH under hypoxic conditions and promotes tumor cell survival and invasion in hypoxic microenvironments. Interrogation of 3,630 human breast cancers provided definitive evidence of CAIX as an independent poor prognostic biomarker for distant metastases and survival. 
Introduction
Cancer metastasis is a complex process that results in establishment of secondary tumors in distant organs (1) . There is increasing recognition that hypoxia plays an important role in cancer progression and metastasis (2, 3) , including breast cancer metastasis (4, 5) . Furthermore, there is now growing evidence that altered tumor metabolism and hypoxia inducible factor 1α (HIF-1α)-regulated enzymes such as carbonic anhydrase IX (CAIX) and CAXII may be vital to the process of tumor progression to metastasis (2, 6) .
CAIX is a dimeric membrane-bound enzyme that efficiently catalyzes the reversible hydration of CO 2 (7, 8) . CAIX is selectively expressed in hypoxic tumors, including breast malignancies (9, 10) , and its presence is a poor prognostic marker for patients with breast cancer (11, 12) . The tumor-specific expression of CAIX and its association with cancer progression and poor treatment outcome has led to interest in targeting this enzyme for cancer therapy (8) . Studies have focused on the utilization of CAIX as a biomarker of hypoxic tumors, spurring the development of specific antibodies and sulfonamide-based small molecules for imaging CAIX in vivo (13) (14) (15) (16) (17) . However, the relevance of CAIX function to the biology of tumors has only recently come into focus.
Evidence suggests that, together with the activity of proteins such as the Na+/H+ exchanger NHE1, Na + -HCO 3 -co-transporters and monocarboxylate transporters MCT-1 and MCT-4 (18, 19) , the activity of CAIX plays an important role in the survival of tumor cells in hypoxic regions of tumors (18, 20) through the regulation of tumor pH (18, 20) . The by CAIX is transported into the cytosol to control an intracellular pH (pHi) that is challenged by the abnormally acidic extracellular pH (pHe) produced in hypoxia (18, (20) (21) (22) . The protons derived from CAIX activity further contribute to the decrease in pHe, thereby potentiating extracellular matrix breakdown and cell invasion (6, 19) . Therefore, CAIX may increase metastatic potential by allowing aggressive tumor cells to survive the hostile environment imposed by hypoxia, and may further function to potentiate extracellular acidosis, facilitating growth and invasion of surviving cells (18, (20) (21) (22) .
Although targeting CAIX for the treatment of cancer has garnered much scientific and clinical interest, appropriate carbonic anhydrase-relevant cell and animal models of tumor hypoxia for testing novel, CAIX-active compounds have only recently become available (23) . To date, studies have focused on the role of CAIX in the regulation of primary tumor growth (22, 24) . Importantly, neither the functional requirement of CAIX in breast tumor growth and metastasis in vivo, nor the benefit of therapeutic targeting this enzyme in aggressive breast cancer has been addressed.
In this study, we provide definitive evidence, using a large (>3600) cohort of human breast cancer samples, that CAIX is a poor prognostic marker for distant metastasis and survival. Furthermore, using a combination of gene depletion strategies and pharmacologic inhibition with novel small molecule inhibitors, we demonstrate a functional requirement of CAIX in the growth and metastasis of mouse and human breast tumors in several pre-clinical models. Our findings establish CAIX as a therapeutic target for the treatment of CAIXpositive breast cancer.
Materials and Methods

Cell culture and hypoxic exposure
The acquisition, generation and culture of the luciferase expressing mouse breast cancer cell lines 4T1, 66cl4 and 67NR have been described previously (25) . The MDA-MB-231 human breast cancer cell line was obtained from the American Type Culture Collection (ATCC) and was maintained as described previously (26) . The MDA-MB-231 LM2-4 Luc+ cell line was provided by Dr.
Robert Kerbel (University of Toronto, Canada) in July, 2010 and cells were cultured as described previously (27) . For in vitro studies, cell lines were passaged for a maximum of 3 months, after which fresh seed stocks were thawed for experimental use. All cells were incubated at 37 O C with 5% CO 2 in a humidified incubator (normoxia). For culture in hypoxia, cells were maintained in 1% O 2 and 5% CO 2 balanced with N 2 at 37 O C in a humidified incubator in a sealed anaerobic workstation.
Cell lines were evaluated routinely for morphology, hypoxia-induced CAIX expression and in vivo tumor growth.
Generation of transfected and transduced cells
shRNAmir vectors targeting mouse CAIX and a non-silencing sequence (Open Biosystems) were transfected into 4T1 cells using LipofectAMINE-PLUS (Invitrogen Life Technologies) according to the manufacturer's instructions.
Transfected cells were selected using hygromycin. Stable shCAIX clones were derived by limited dilution cloning. For (re-)introduction of CAIX, human CAIX
7
(gift from Dr. Jacques Pouysségur, University of Nice) was transfected into 4T1 cells stably expressing mouse shCAIX and Zeocin was used for selection.
For stable depletion of human CAIX in the MDA-MB-231 cells, two different shRNAmir constructs (Open Biosystems) were transduced into cells using lentivirus as per the manufacturer's instructions. Tranduced cells were selected using puromycin.
All transfected and transduced cell lines were selected, propogated and frozen as seed stocks at early passage. For in vivo studies, cells were thawed from frozen stocks, passaged 1-2 times to expand the culture and implanted in
mice. Cell lines were tested for mycoplasma contamination by a commercial testing facility prior to implantation in mice.
Measurement of extracellular pH
Changes in pHe were assessed using procedures published previously (28) (29) (30) .
In brief, cells were plated and allowed to recover overnight. A standard volume of 3 ml of fresh media/dish was then added and cells were incubated in normoxia or hypoxia for 72 h. Care was taken to ensure that cultures grown in normoxia and hypoxia were subconfluent and contained similar cell numbers. Media was collected and pH was measured immediately using a digital pH meter.
Pharmacological Inhibitors
The chemical properties of the sulfonamide, CAI17, have been described previously (8, 30) . For in vitro studies, CAI17 was dissolved in DMSO, stored at - 
Analysis of protein expression
Cells or flash-frozen tumor tissues were lysed as described previously (26) .
Equal amounts of protein were loaded on SDS-PAGE gels. Western blots were performed as described previously (26) using mouse CAIX (1:500), human CAIX (1:1000) (R&D Systems), caspase 3 (1:1000; Cell Signaling), PARP-1 (1:1000;
Cell Signaling) and β-actin (1:10,000, Sigma) antibodies.
Mouse tumor models
All animal studies and procedures were done in accordance with protocols approved by the Institution Animal Care Committee at the BC Cancer research Centre and the University of British Columbia (Vancouver, BC, Canada). ) were orthotopically implanted into the fourth mammary fat pad of 7-9 week-old female BALB/c mice as described previously (25) . Primary tumor growth rates were calculated from caliper measurements using the modified ellipsoid formula (LxW and metastasis progression was monitored and quantified using bioluminescent imaging as previously described (25, 27) .
Syngeneic orthotopic tumors and spontaneous metastasis
Experimental metastasis assays
For studies involving genetic depletion of CAIX, 4T1 or 67NR cells (5x10 then harvested and analyzed for vasculature, perfusion, hypoxia, apoptosis, proliferation and necrosis as described previously (31, 32) . Paraffin embedded tumor sections were also stained for CAIX (1:50 for lung metastases, Santa Cruz Biotechnology) as previously described (25) . 
Human xenograft tumors
Clinical Analysis
The methods used to create the TMAs have been described (33) . 3,630 cases had adequate tumor and staining results for assessment of all biomarkers.
Immunohistochemistry for ER, PR, HER2, CK 5/6, EGFR and Ki67 was performed concurrently on serial sections and scored as described previously (33) . CAIX expression was assessed using a murine monoclonal antibody (M75; 
Statistical Analysis
Results were subjected to statistical analysis using the Data Analysis ToolPack in Excel software. Two-tailed p values were calculated using Student's t-test. Data were considered significant for p<0.05. Statistical analysis for the clinical outcomes was performed using SPSS 13.0 (Chicago, IL), S-Plus 6.2 (Seattle, WA) and R 2.1.1 (http://www.r-project.org). In univariate analysis, BCSS (date of diagnosis of primary breast cancer to date of death with breast cancer as the primary or underlying cause) and RFS (date of diagnosis of primary breast cancer to the date of a local, regional or distant recurrence) and distant RFS (date of diagnosis of primary breast cancer to the date of a distant recurrence)
were estimated by Kaplan-Meier curves. Log-rank test was used to estimate the survival differences. For multivariate analysis, a Cox proportional hazards model was used to estimate the adjusted hazard ratios and significance. To assess the violations of proportional hazard models, smoothed plots of weighted Schoenfeld residuals were used.
Results and Discussion
CAIX is a poor prognostic marker in a large cohort of breast cancer patients
Although previous studies have reported that CAIX expression in several types of cancer, including breast cancer, correlates with poor patient prognosis (11, 34, 36, 37) treatments not uniform. To provide definitive evidence for CAIX as an important breast cancer prognostic marker, we analyzed the expression of CAIX in a primary breast tumor tissue microarray (TMA) containing more than 3600 patient samples subjected to standardized treatment with a median follow-up of 10.5 years (Table S1 ). Previously, we demonstrated prognostic significance of CAIX in a cohort of 103 breast cancers in which CAIX expression was examined both as a continuous and a categorical variable (11) . We found that even 1% staining was significantly prognostic. For the large cohort of patients examined here, a simplified scoring system (present vs absent) allows for less analytical variability, an issue which plagues immunohistochemical testing for hormone receptors and the HER-2 receptor in breast cancer. CAIX expression was seen in 15.6% of assessable tumors and CAIX was differentially expressed among the biological subtypes, with the highest correlation in the basal breast cancers (51%) and the lowest proportion in the luminal A subtype (8%) ( Table S2 ).
In Kaplan-Meier analyses, CAIX expression was significantly associated with worse relapse free survival ( Figure 1A ), distant relapse free survival ( Figure   1B ) and breast cancer specific survival ( Figure 1C ), achieving very high levels of statistical significance. The 10 year distant relapse free survival and breast cancer specific survival rates in the CAIX positive versus CAIX negative groups were 57% compared to 73%, and 62% compared to 78%, respectively. In multivariate analyses, including all standard prognostic variables and biological subtypes, CAIX expression remained a strong independent poor prognostic factor with a hazard ratio of 1.4 (Table S3 ). These data confirm and extend the results of previous studies, and demonstrate a clear link between CAIX expression and a higher rate of distant metastasis for breast cancer. Our data substantiate previous studies that have also shown CAIX as a poor prognostic marker of breast cancer (11, 12) . In addition, other studies have shown a clear correlation between the expression of CAIX, hypoxia-induced HIF-1α and altered metabolic proteins such as GLUT-1 (4, 9, 38), althoughHIF-1α is a more labile protein, and thus more susceptible to pre-analytical variables.
Preclinical models for interrogating the requirement of hypoxia-induced CAIX expression in breast cancer
Tumor hypoxia is linked both to the expression of CAIX and to the selection of tumor cells that are better able to metastasize. However, while a few studies have investigated the role of CAIX in the regulation of primary tumor growth (22, 24) , the relationship between CAIX expression and metastatic potential has not been investigated. Therefore, to interrogate the functional role of CAIX in metastatic breast cancer, we were interested in selecting tumor models that exhibit both hypoxic microenvironments and the ability to metastasize. We have shown previously that the highly metastatic 4T1 mouse mammary tumor (39) overexpresses CAIX (25) . 
sequences targeting human CAIX were transduced and hypoxia-induced CAIX expression was analyzed. Only one of the transduced shRNA constructs was found to effectively deplete CAIX expression ( Figure 3B , Supplemental Figure   1C ). The cell line expressing the "non-silencing" CAIX shRNA sequence was used as a control in subsequent in vivo experiments.
Recent data suggest that the regulation of pH by CAIX may be important for cell survival in conditions of hypoxic stress (22, 42) and previous studies have Figure 2A) or PARP cleavage (Supplemental Figure 2B) was observed, suggesting that cell death in the CAIX-depleted cells may be occurring by a caspase-independent mechanism, possibly related to depletion of the intracellular ATP concentration (Supplemental Figure 2C) . While the decrease in ATP concentration was modest, it was statistically significant and similar in magnitude to data reported previously (43) .
CAIX is functionally linked to the control of tumor pH (18, 22, 42) , and hypoxia-induced, extracellular acidosis is a measure of the biological activity of CAIX in cultured cells (30) . Therefore, we examined the effect of CAIX depletion on pHe in hypoxia. Acidification of the extracellular medium in hypoxia was inhibited in the shCAIX-expressing 4T1 clones relative to the parental and shNSexpressing 4T1 cells (Figure 3D ), suggesting that silencing CAIX gene expression induces functional inhibition of pHe regulation in this cell line.
Depletion of CAIX expression results in regression or growth inhibition of mouse and human breast tumors
Having evaluated the biological response of 4T1 cells to CAIX depletion in vitro, we next tested the impact of silencing CAIX expression on the growth of these tumors in vivo. We observed that whereas control 4T1 cells formed tumors that grew steadily over 30 days, tumors established from CAIX-depleted cells regressed significantly after initial tumor growth ( Figure 4A ). The regression of the tumors appeared to be stable, as there were only two mice with primary tumor recurrence appearing towards the end of the study (Table S4) .
Examination of the primary tumors confirmed downregulation of CAIX expression in the tumors (Supplemental Figure 3) . The reduction of CAIX expression had a dramatic effect on the overall survival of the mice ( Figure 4B ). While the animals bearing tumors that express CAIX did not survive, the survival rate of animals inoculated with CAIX-depleted 4T1 cells remained at 100% over the course of the study.
To validate the observed in vivo effects of CAIX depletion on primary breast tumor growth, we performed similar experiments using the MDA-MB-231 cells expressing human shCAIX (see Figure 3B 
Inhibition of CAIX inhibits metastasis of 4T1 breast tumors
While a reduction in colon tumor growth in response to CAIX depletion has been demonstrated previously (22) and CAIX has been shown to influence cell migration in vitro (45), CAIX has not been previously linked to metastasis in vivo. CAN-10-4261 impermeant derivatives of acetazolamide, a general carbonic anhydrase inhibitor, resulted in inhibition of tumor growth compared to vehicle-treated controls (24) .
These data have provided initial proof of principle for sulfonamide-based antitumor effects, but acetazolamide lacks specificity for CAIX. First, we investigated the ability of the metastatic and non-metastatic cells to bind to a previously described, highly selective sulfonamide-based inhibitor of CAIX (CAI17) with a Ki in vitro of 24 nM (8). This fluorescent inhibitor ( Figure 6A) interacts only with active CAIX in hypoxic conditions (8) and has been used successfully to image hypoxic xenografts (15) . Similar to findings in MDCK cells expressing CAIX (30), we observed that the inhibitor was not able to bind appreciably 4T1 or 67NR cells in normoxia ( Figure 6A ). In contrast, CAI17 bound to the cell surfaces of metastatic, CAIX-expressing 4T1 cells cultured in hypoxia, but not the non-metastatic, CAIX-negative 67NR cells cultured in similar conditions ( Figure 6A ). We next tested the effect of CAI17 on hypoxia-induced changes in pHe in these two cell types. In the absence of the inhibitor, the pHe of cultured 4T1 cells decreased significantly in hypoxia, but remained unchanged in the 67NR cultures ( Figure 6A CAN-10-4261 activity of CAI17, we took advantage of the 67NR tumor model as a negative control. We treated 67NR cell-derived tumors using a dosing schedule and concentrations of CAI17 identical to those used for the 4T1 model ( Figure 6C ).
There was no effect of the CAI17 compound relative to the vehicle control, even at the highest concentration of the inhibitor ( Figure 6C) .
The inhibitor concentrations and the dosing schedule were well-tolerated, and no significant weight reduction was noted in any of the treated mice (Supplemental Figure 5A and 5B). In addition to CAI17, we tested the effect of a novel ureido-sulfonamide inhibitor of CAIX, U-104 ( Figure 6D , Table 1 ), on primary breast tumor growth using a highly metastatic variant of the MDA-MB-231 cell line (27) . These cells were observed to induce robustly CAIX in hypoxia ( Figure 6D , inset). Tumor volume measurements showed significant inhibition of primary tumor growth in the mice treated with the U-104 compound compared to vehicle controls ( Figure   6D ). Taken together, these data suggest the ability of sulfonamide-based CAIX inhibitors to specfically target CAIX-expressing tumors.
Having demonstrated that selective sulfonamide-based compounds inhibit the growth of primary breast tumors, we next tested U-104 for its ability to inhibit treating metastatic disease in breast cancer. Further structure/function analyses for the ureido-sulfonamide compounds will be described elsewhere (46) . (Table S2 ). Since these subgroups of breast cancers are the most difficult to treat and are also the most aggressive in terms of metastatic potential, we suggest that CAIX inhibitors, such as those described here, should be used to treat hypoxic breast tumors with elevated CAIX expression. The development of small molecule inhibitors of CAIX activity (8) , anti-CAIX neutralizing antibodies, and CAIX imaging agents, should accelerate clinical translation of our findings.
Finally, our findings are likely to be applicable to other CAIX-expressing tumors. *KI values were derived using in vitro assays for CA activity as described in (47). The indicated cell lines were cultured in normoxia or hypoxia and levels of CAIX expression were analyzed by Western blot. β-actin served as a loading control. 
